StreetAlpha.app
Home › Stocks › KRYS

Krystal Biotech, Inc. (KRYS)

Healthcare
$308.89
▼ −2.19%
LAST CLOSE · NOV 20

Krystal Biotech develops and makes gene therapies, including VYJUVEK, a topical treatment for a rare inherited skin disease. It last closed at $308.89 on Nov 20, down 2.19% on the day. The next earnings report for KRYS is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, KRYS reported EPS of $2.05 on revenue of $127.3M, with revenue up 30.2% from a year ago. Over its last 8 reports the stock moved an average of 7.4% the session after earnings. Over the last 12 months KRYS insiders bought $0 of stock on the open market and sold $105.3M, according to SEC Form 4 filings.

AI Auto Pilots
Is KRYS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold KRYS.

Key Stats

Last 12 months
Results
Revenue
$470.0M
+26.0% vs a year ago
Net income
$225.2M
+13.2% vs a year ago
EPS (diluted)
$7.36
+10.3% vs a year ago
Free cash flow
$310.1M
66.0% margin
Valuation
Market cap
$9.2B
29.6M shares
P/E
42.0
Price over 12 month EPS
Price to sales
19.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$462.8M
At Sep 30
Shareholder equity
$1.4B
Shares outstanding
29.6M
At Oct 28
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $0$0FY2021FY2022: $0$0FY2022FY2023: $50.7M$50.7MFY2023FY2024: $290.5M$290.5MFY2024FY2025: $389.1M$389.1MFY2025

From KRYS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 2). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · Time not announced
Reported EPS
$2.05
Quarter ended Sep 2026
Year ago EPS
$2.66
−22.9% on a GAAP basis
Revenue
$127.3M
+30.2% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $1.53Dec '24Mar 2025: $1.20Mar '25Jun 2025: $1.29Jun '25Sep 2025: $2.66Sep '25Dec 2025: $1.70Dec '25Mar 2026: $1.83Mar '26Jun 2026: $1.79Jun '26Sep 2026: $2.05Sep '26Latest $2.05
Revenue by quarter
Dec 2024: $91.1MDec '24Mar 2025: $88.2MMar '25Jun 2025: $96.0MJun '25Sep 2025: $97.8MSep '25Dec 2025: $107.1MDec '25Mar 2026: $116.4MMar '26Jun 2026: $119.2MJun '26Sep 2026: $127.3MSep '26Latest $127.3M
How KRYS moved after its last 8 reports
Average move the session after a report ±7.4%
Nov 2, 2026Time not announced−10.9%
Aug 3, 2026Time not announced−8.4%
Feb 17, 2026Time not announced+4.1%
Jan 12, 2026Time not announced+4.1%
Nov 3, 2025Time not announced+0.2%
Aug 4, 2025Time not announced−14.0%
May 6, 2025Time not announced−14.1%
Nov 4, 2024Time not announced−3.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on KRYSStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on KRYS
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on KRYS

Technical Analysis

KRYS · as of the Nov 20 close · updated each morning
Turning down

The stock is 0% below its 20 day and 4% below its 50 day average. It is sitting right on its 200 day average, a level many traders watch. Momentum is improving (RSI 47). The nearest support is the Pivot S1 at $304.32, and the nearest resistance the 20 day average at $309.56.

Short trendBearish
Long trendNeutral
MomentumImproving
StretchNormal
VolatilityNormal, 3.7%/day
Key levels
$382.5452 week high+23.8%
$335.11100 day average+8.5%
$322.4950 day average+4.4%
$317.37Pivot R1+2.7%
$312.79Pivot+1.3%
$311.05Swing high (Nov 11)+0.7%
$310.50200 day average+0.5%
$309.5620 day average+0.2%
$308.89Last close
$304.32Pivot S1−1.5%
$297.52Swing low (Nov 9)−3.7%
$203.1752 week low−34.2%
Indicators
RSI (14)47.27Middle of its rangeNeutral
MACD-4.22Above its signal lineBullish
Stochastic68.6Middle of its rangeNeutral
ADX (14)16.8No clear trend
Williams %R-45.3Oversold below −80, overbought above −20Neutral
CCI (20)35.7Oversold below −100, overbought above 100Neutral
Rate of change+2.7%Change over 10 sessionsBullish
ATR (14)$11.42Typical daily range, 3.7% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for KRYS

What happened before

See how KRYS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow KRYS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How KRYS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for KRYSHow many large options trades hit KRYS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

KRYS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲256 buying vs 177 selling
  • ▼Held by funds -4.3 pts
  • ▲Funds holding +16
  • ▲Superinvestors: 3 added, 0 cut
  • ▼Put/call 2.02 to 3.30
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding442426+3.8%
In funds' top 10912−25.0%
Held by funds97.9%102.2%−4.3 pts
New / increased76 / 18091 / 175−3.8%
Reduced / sold out122 / 55110 / 37+20.4%
Put/call ratio3.302.02+63.8%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See KRYS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

KRYS Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$105.3M16 sales · 6 insiders
87% of the selling was under pre-arranged trading plans.
2025-12 sold $22.0M2026-02 sold $27.8M2026-03 sold $13.4M2026-05 sold $194K2026-06 sold $15.8M2026-08 sold $8.2M2026-09 sold $18.0MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 4Krish S KrishnanPresident and CEOSale plan25,000$359.32$9.0M
Sep 4Suma KrishnanPresident, R&DSale plan25,000$359.32$9.0M
Aug 14Dino A RossiDirectorSale25,000$329.12$8.2M
Jun 25John Charles ThomasEVP, General CounselSale plan1,000$347.27$347K
Jun 4Krish S KrishnanPresident and CEOSale plan25,000$308.12$7.7M
Jun 4Suma KrishnanPresident, R&DSale plan25,000$308.11$7.7M
Every insider buy and sale for KRYS over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See KRYS insider trades →

From SEC Form 4 filings by KRYS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether KRYS is in one of them and how their past KRYS trades turned out.

KRYS in the AI portfolios
Loading…

KRYS News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered KRYS in an article yet. Here's the latest on the wider market.

KRYS in the news

KRYS Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Jan 20
Who traded KRYS · since 2022
Latest 1 filing
$1K – $15KTraded Dec 12, 2022Filed Jan 20, 2023
PersonTypeAmountTradedFiledDelay
Christopher JacobsR · NYBuy$1K – $15KDec 12, 2022Jan 20, 202339 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Krystal Biotech

Krystal Biotech is a biotechnology company based in Pittsburgh, Pennsylvania, that develops and manufactures gene therapies. Its platform uses an engineered herpes simplex virus to deliver therapeutic genes to target cells. Its approved product, VYJUVEK, is applied directly to the skin to treat dystrophic epidermolysis bullosa, a rare inherited skin disease, and is sold in the United States, Europe and Japan. The company also has clinical stage candidates for other rare diseases.

Headquarters
Pittsburgh, PA